(NTR) Nutrien - Ratings and Ratios
Fertilizer, Crop Protection, Seed, Nutrient, Services
NTR EPS (Earnings per Share)
NTR Revenue
Description: NTR Nutrien October 14, 2025
Nutrien Ltd. (NYSE: NTR) is the world’s largest provider of crop inputs and services, organized into four operating segments: Nutrien Ag Solutions, Potash, Nitrogen, and Phosphate. The Ag Solutions arm sells nutrients, crop-protection chemicals, seeds and related merchandise, and also delivers agronomic services such as soil and leaf testing, precision-ag technology, water management, and financing to growers.
The Potash segment produces both granular and standard potash fertilizers, while the Nitrogen segment offers a portfolio that includes ammonia, urea, “environmentally smart” nitrogen products, nitrates and sulfates. The Phosphate segment supplies solid and liquid phosphate fertilizers as well as industrial and feed-grade phosphate products.
Key financial and operational metrics (2023) include roughly $27 billion in revenue, an EBITDA margin near 15 %, and net debt of about $6 billion. Production capacity is roughly 14 million tonnes of potash, 10 million tonnes of nitrogen, and 6 million tonnes of phosphate, positioning the firm to meet a sizable share of global fertilizer demand.
Primary economic drivers for Nutrien are global grain and oilseed production growth (which fuels fertilizer consumption), commodity price cycles for nitrogen, potash and phosphate, and regulatory trends that incentivize lower-emission nitrogen use. A sector-wide catalyst is the accelerating adoption of precision agriculture and digital agronomy services, which can boost the value of Nutrien’s Ag Solutions offerings.
For a deeper quantitative dive into Nutrien’s valuation metrics and scenario analysis, the ValueRay platform offers a free, data-rich snapshot worth exploring.
NTR Stock Overview
| Market Cap in USD | 26,403m |
| Sub-Industry | Fertilizers & Agricultural Chemicals |
| IPO / Inception | 2018-01-02 |
NTR Stock Ratings
| Growth Rating | 15.5% |
| Fundamental | 48.9% |
| Dividend Rating | 66.5% |
| Return 12m vs S&P 500 | -7.74% |
| Analyst Rating | 3.88 of 5 |
NTR Dividends
| Dividend Yield 12m | 3.99% |
| Yield on Cost 5y | 6.38% |
| Annual Growth 5y | 4.66% |
| Payout Consistency | 100.0% |
| Payout Ratio | 70.9% |
NTR Growth Ratios
| Growth Correlation 3m | 26.7% |
| Growth Correlation 12m | 81.4% |
| Growth Correlation 5y | -14.2% |
| CAGR 5y | -5.86% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.13 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.21 |
| Sharpe Ratio 12m | 0.88 |
| Alpha | -3.36 |
| Beta | 1.178 |
| Volatility | 28.96% |
| Current Volume | 1759.1k |
| Average Volume 20d | 2090k |
| Stop Loss | 52.8 (-3.2%) |
| Signal | -0.27 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (1.36b TTM) > 0 and > 6% of Revenue (6% = 1.56b TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -1.83pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.79% (prev 11.61%; Δ 3.19pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 3.67b > Net Income 1.36b (YES >=105%, WARN >=100%) |
| Net Debt (12.25b) to EBITDA (4.99b) ratio: 2.45 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.33 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (487.6m) change vs 12m ago -1.48% (target <= -2.0% for YES) |
| Gross Margin 29.18% (prev 29.23%; Δ -0.05pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 48.88% (prev 50.66%; Δ -1.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.70 (EBITDA TTM 4.99b / Interest Expense TTM 707.5m) >= 6 (WARN >= 3) |
Altman Z'' 2.46
| (A) 0.07 = (Total Current Assets 15.62b - Total Current Liabilities 11.77b) / Total Assets 53.26b |
| (B) 0.22 = Retained Earnings (Balance) 11.72b / Total Assets 53.26b |
| (C) 0.05 = EBIT TTM 2.62b / Avg Total Assets 53.12b |
| (D) 0.89 = Book Value of Equity 25.03b / Total Liabilities 28.14b |
| Total Rating: 2.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 48.87
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 4.43% = 2.22 |
| 3. FCF Margin 6.60% = 1.65 |
| 4. Debt/Equity 0.54 = 2.36 |
| 5. Debt/Ebitda 2.45 = -0.87 |
| 6. ROIC - WACC (= -1.81)% = -2.27 |
| 7. RoE 5.54% = 0.46 |
| 8. Rev. Trend -17.66% = -1.32 |
| 9. EPS Trend -36.96% = -1.85 |
What is the price of NTR shares?
Over the past week, the price has changed by -5.18%, over one month by -8.12%, over three months by -6.81% and over the past year by +11.99%.
Is Nutrien a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NTR is around 52.22 USD . This means that NTR is currently overvalued and has a potential downside of -4.24%.
Is NTR a buy, sell or hold?
- Strong Buy: 10
- Buy: 5
- Hold: 8
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the NTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 67.7 | 24.1% |
| Analysts Target Price | 67.7 | 24.1% |
| ValueRay Target Price | 57.5 | 5.5% |
NTR Fundamental Data Overview October 31, 2025
P/E Trailing = 19.5396
P/E Forward = 11.8483
P/S = 1.0553
P/B = 1.1571
P/EG = 0.6101
Beta = 1.178
Revenue TTM = 25.96b USD
EBIT TTM = 2.62b USD
EBITDA TTM = 4.99b USD
Long Term Debt = 9.87b USD (from longTermDebt, last quarter)
Short Term Debt = 2.78b USD (from shortTermDebt, last quarter)
Debt = 13.64b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.25b USD (from netDebt column, last quarter)
Enterprise Value = 38.65b USD (26.40b + Debt 13.64b - CCE 1.39b)
Interest Coverage Ratio = 3.70 (Ebit TTM 2.62b / Interest Expense TTM 707.5m)
FCF Yield = 4.43% (FCF TTM 1.71b / Enterprise Value 38.65b)
FCF Margin = 6.60% (FCF TTM 1.71b / Revenue TTM 25.96b)
Net Margin = 5.25% (Net Income TTM 1.36b / Revenue TTM 25.96b)
Gross Margin = 29.18% ((Revenue TTM 25.96b - Cost of Revenue TTM 18.39b) / Revenue TTM)
Gross Margin QoQ = 30.42% (prev 25.88%)
Tobins Q-Ratio = 0.73 (Enterprise Value 38.65b / Total Assets 53.26b)
Interest Expense / Debt = 1.14% (Interest Expense 155.0m / Debt 13.64b)
Taxrate = 24.46% (398.0m / 1.63b)
NOPAT = 1.98b (EBIT 2.62b * (1 - 24.46%))
Current Ratio = 1.33 (Total Current Assets 15.62b / Total Current Liabilities 11.77b)
Debt / Equity = 0.54 (Debt 13.64b / totalStockholderEquity, last quarter 25.09b)
Debt / EBITDA = 2.45 (Net Debt 12.25b / EBITDA 4.99b)
Debt / FCF = 7.15 (Net Debt 12.25b / FCF TTM 1.71b)
Total Stockholder Equity = 24.62b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.56% (Net Income 1.36b / Total Assets 53.26b)
RoE = 5.54% (Net Income TTM 1.36b / Total Stockholder Equity 24.62b)
RoCE = 7.59% (EBIT 2.62b / Capital Employed (Equity 24.62b + L.T.Debt 9.87b))
RoIC = 5.31% (NOPAT 1.98b / Invested Capital 37.24b)
WACC = 7.12% (E(26.40b)/V(40.04b) * Re(10.36%) + D(13.64b)/V(40.04b) * Rd(1.14%) * (1-Tc(0.24)))
Discount Rate = 10.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.74%
[DCF Debug] Terminal Value 62.24% ; FCFE base≈2.10b ; Y1≈1.46b ; Y5≈744.3m
Fair Price DCF = 21.04 (DCF Value 10.22b / Shares Outstanding 485.9m; 5y FCF grow -35.86% → 3.0% )
EPS Correlation: -36.96 | EPS CAGR: -75.63% | SUE: -4.0 | # QB: 0
Revenue Correlation: -17.66 | Revenue CAGR: 9.23% | SUE: -0.02 | # QB: 0
Additional Sources for NTR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle